Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Cardiology

The Science of Naxos: Biology, Genetics, and Diagnosis

At a Glance

Naxos disease is an inherited condition caused by changes in both copies of the JUP gene. It weakens cell connections in the skin and heart, causing woolly hair, thickened palms and soles, heart muscle damage, and rhythm problems; diagnosis combines genetic testing with heart tests.

Naxos disease is a genetic condition that affects the way your body’s cells are held together. To understand why it affects both the heart and the skin, it helps to look at the microscopic “glue” that keeps our tissues strong [1][2].

The Biology of “Cellular Glue”

Your heart and skin cells are connected by specialized structures called desmosomes. Think of desmosomes as the “glue” or mechanical rivets that hold cells together, allowing them to withstand the constant stress of the heart beating and the skin moving [3][4].

In Naxos disease, a mutation in the JUP gene (which provides instructions for a protein called plakoglobin) causes this glue to be weak or insufficient [1][5]. When these tissues are under mechanical stress, the weak “glue” can fail:

  • In the Skin and Hair: This leads to the characteristic woolly hair and the thickening of the skin on the palms and soles [6][7].
  • In the Heart: Over time, the stress of the heart’s constant pumping causes heart muscle cells to pull apart and die [7]. The body attempts to repair this damage by replacing the lost muscle with fatty and fibrous scar tissue [8]. This scarring is what causes the heart to weaken and disrupts the electrical signals that keep the heart beating in a steady rhythm [5].

Genetic Inheritance: What It Means for Families

Naxos disease follows an autosomal recessive inheritance pattern [1]. This means:

  • Carrier Parents: Both parents are typically “carriers.” They have one healthy copy of the gene and one mutated copy. Carriers usually show no symptoms of classic Naxos disease [9].
  • The Inheritance Probabilities: When two carriers have a child, there is a 25% chance the child will inherit two mutated copies (biallelic) and have Naxos disease. There is a 50% chance the child will inherit one mutated copy and be a carrier (like the parents), and a 25% chance they will inherit neither [9].
  • Siblings: Because this is inherited, siblings should be evaluated by a medical geneticist and a cardiologist [10][11]. Individuals with only one familial variant are usually carriers and do not typically develop classic Naxos cardiomyopathy. Note that a “Variant of Uncertain Significance” (VUS) should not be used to guide medical decisions or impose lifestyle restrictions, as it may be reclassified later by genetics experts.

Naxos vs. Carvajal Syndrome

Naxos disease is often confused with another condition called Carvajal syndrome. While they look similar on the outside, they are different at the genetic level:

  • Naxos Disease: Caused by the JUP gene. It often primarily affects the right side of the heart (the right ventricle) [5].
  • Carvajal Syndrome: Caused by the DSP gene. It often affects the left side of the heart (the left ventricle) or both sides, and can sometimes lead to heart issues earlier in childhood [12][13].

How Doctors Reach a Diagnosis

Diagnosing the cardiac part of Naxos disease requires putting together multiple pieces of information. Doctors use two main sets of professional guidelines: the 2010 Task Force Criteria and the newer 2020 Padua Criteria (which better identifies issues on the left side or both sides of the heart) [14][15].

To evaluate these criteria, your team will use:

  1. Electrocardiogram (ECG): To look for electrical changes. While doctors sometimes look for “epsilon waves,” these are uncommon and their absence does not exclude the disease [8][16].
  2. Echocardiogram: An ultrasound that gives a baseline view of the heart’s size and pumping power [17].
  3. Cardiac MRI (CMR): An imaging tool used to spot the fibrous scar tissue (a finding known as Late Gadolinium Enhancement) [17][9]. It has limitations in children, such as the need for sedation and contrast exposure, and it is not guaranteed to catch the “very first” change in every patient.
  4. Genetic Testing: A blood test to identify specific JUP mutations. Genetics are complementary and must be interpreted by a specialist [18][19].

Common questions in this guide

What causes Naxos disease?
Naxos disease is caused by disease-causing changes in both copies of the JUP gene, which makes plakoglobin. This protein helps desmosomes hold cells together, so weakened cell connections can affect the skin, hair, heart muscle, and heart rhythm.
How is Naxos disease inherited?
Naxos disease follows an autosomal recessive pattern. When both parents are carriers, each child has a 25% chance of inheriting two altered copies and having the disease, a 50% chance of being a carrier, and a 25% chance of inheriting neither altered copy.
Does having one JUP variant mean I have Naxos disease?
A person with only one familial JUP variant is usually a carrier and does not typically develop classic Naxos cardiomyopathy. A variant of uncertain significance should not by itself be used to make medical decisions or impose activity restrictions; a genetics specialist should interpret the result.
How are Naxos disease and Carvajal syndrome different?
Naxos disease is linked to JUP mutations and often mainly affects the right ventricle. Carvajal syndrome is linked to DSP mutations and more often affects the left ventricle or both sides of the heart, sometimes earlier in childhood.
What tests are used to diagnose the heart problems associated with Naxos disease?
Doctors combine the clinical picture with an ECG, echocardiogram, cardiac MRI, and genetic testing. They may use the 2010 Task Force Criteria and 2020 Padua Criteria, and the absence of epsilon waves does not exclude the disease.
Why should siblings of someone with Naxos disease be evaluated?
Because Naxos disease is inherited, siblings may have inherited two altered JUP copies even if they have few or no symptoms. A medical geneticist and cardiologist can determine which genetic and heart evaluations are appropriate and explain how the results affect activity recommendations.

Get notified when new evidence is published on Naxos disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (19)
  1. 1

    Normalization of Naxos plakoglobin levels restores cardiac function in mice.

    Zhang Z, Stroud MJ, Zhang J, et al.

    The Journal of clinical investigation 2015; (125(4)):1708-12.

    PMID: 25705887
  2. 2

    Generation of a CRISPR/Cas9-edited Plakoglobin (JUP) knock-out (JMUi001-A-4) iPSC line to model the cardiac phenotype of arrhythmogenic cardiomyopathy.

    Walz K, Janz A, Klopocki E, Gerull B

    Stem cell research 2023; (73()):103240 doi:10.1016/j.scr.2023.103240.

    PMID: 37995437
  3. 3

    Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy.

    Smith ED, Lakdawala NK, Papoutsidakis N, et al.

    Circulation 2020; (141(23)):1872-1884 doi:10.1161/CIRCULATIONAHA.119.044934.

    PMID: 32372669
  4. 4

    Left-dominant arrhythmogenic cardiomyopathy due to desmoplakin mutation: a case report.

    Lemus Barrios GA, Lopez-Lopez JP, Barbosa-Balaguera S, Correa AM

    ESC heart failure 2023; (10(5)):3190-3194 doi:10.1002/ehf2.14504.

    PMID: 37632291
  5. 5

    Naxos disease - a narrative review.

    Leopoulou M, Mattsson G, LeQuang JA, et al.

    Expert review of cardiovascular therapy 2020; (18(11)):801-808 doi:10.1080/14779072.2020.1828064.

    PMID: 32966140
  6. 6

    Towards a Better Understanding of Genotype-Phenotype Correlations and Therapeutic Targets for Cardiocutaneous Genes: The Importance of Functional Studies above Prediction.

    Vermeer MCSC, Andrei D, Marsili L, et al.

    International journal of molecular sciences 2022; (23(18)) doi:10.3390/ijms231810765.

    PMID: 36142674
  7. 7

    Naxos Disease and Related Cardio-Cutaneous Syndromes.

    Protonotarios A, Asimaki A, Basso C, et al.

    JACC. Advances 2025; (4(2)):101547 doi:10.1016/j.jacadv.2024.101547.

    PMID: 39877668
  8. 8

    Cardiocutaneous syndrome (Naxos disease) in a Bangladeshi boy.

    Islam AM, Rahman MT, Chowdhury AH

    Cardiovascular diagnosis and therapy 2016; (6(5)):462-465 doi:10.21037/cdt.2016.03.07.

    PMID: 27747171
  9. 9

    Imaging Naxos disease and related cardiocutaneous syndromes: the NAXCARE multimodality approach.

    Protonotarios I, Alsergani H, Anastasakis A, et al.

    Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 2026; doi:10.1016/j.hjc.2026.03.007.

    PMID: 41936932
  10. 10

    Arrhythmogenic right ventricular cardiomyopathy in patients with biallelic JUP-associated skin fragility.

    Vahidnezhad H, Youssefian L, Faghankhani M, et al.

    Scientific reports 2020; (10(1)):21622 doi:10.1038/s41598-020-78344-9.

    PMID: 33303784
  11. 11

    Genotype and cardiac outcome in patients with cardiocutaneous syndrome (Naxos disease variant: Carvajal syndrome).

    Binfadel M, Aleem MU, Alhabdan M, et al.

    Orphanet journal of rare diseases 2025; (20(1)):137 doi:10.1186/s13023-025-03612-8.

    PMID: 40108711
  12. 12

    Arrhythmogenic Right Ventricular Cardiomyopathy in Pediatric Patients: An Important but Underrecognized Clinical Entity.

    Te Riele ASJM, James CA, Calkins H, Tsatsopoulou A

    Frontiers in pediatrics 2021; (9()):750916 doi:10.3389/fped.2021.750916.

    PMID: 34926342
  13. 13

    Carvajal Syndrome- A Variant of Naxos Disease: A Case Report.

    Mandal KD, Shrestha PN, Ghimire A, et al.

    JNMA; journal of the Nepal Medical Association 2022; (60(246)):187-191 doi:10.31729/jnma.7102.

    PMID: 35210635
  14. 14

    The 2020 "Padua Criteria" for Diagnosis and Phenotype Characterization of Arrhythmogenic Cardiomyopathy in Clinical Practice.

    Graziano F, Zorzi A, Cipriani A, et al.

    Journal of clinical medicine 2022; (11(1)) doi:10.3390/jcm11010279.

    PMID: 35012021
  15. 15

    Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria.

    Corrado D, Perazzolo Marra M, Zorzi A, et al.

    International journal of cardiology 2020; (319()):106-114 doi:10.1016/j.ijcard.2020.06.005.

    PMID: 32561223
  16. 16

    Natural Course of Electrocardiographic Features in Arrhythmogenic Right Ventricular Cardiomyopathy and Their Relation to Ventricular Arrhythmic Events.

    Svensson A, Jensen HK, Boonstra MJ, et al.

    Journal of the American Heart Association 2024; (13(16)):e031893 doi:10.1161/JAHA.123.031893.

    PMID: 39158567
  17. 17

    Multimodality Imaging in Arrhythmogenic Right Ventricular Cardiomyopathy.

    Malik N, Mukherjee M, Wu KC, et al.

    Circulation. Cardiovascular imaging 2022; (15(2)):e013725 doi:10.1161/CIRCIMAGING.121.013725.

    PMID: 35147040
  18. 18

    International Evidence Based Reappraisal of Genes Associated With Arrhythmogenic Right Ventricular Cardiomyopathy Using the Clinical Genome Resource Framework.

    James CA, Jongbloed JDH, Hershberger RE, et al.

    Circulation. Genomic and precision medicine 2021; (14(3)):e003273 doi:10.1161/CIRCGEN.120.003273.

    PMID: 33831308
  19. 19

    Value of genetic testing in the diagnosis and risk stratification of arrhythmogenic right ventricular cardiomyopathy.

    de Brouwer R, Bosman LP, Gripenstedt S, et al.

    Heart rhythm 2022; (19(10)):1659-1665 doi:10.1016/j.hrthm.2022.05.038.

    PMID: 35688345

This page explains Naxos disease biology, inheritance, and testing for informational purposes only; it does not constitute medical advice. Your cardiologist and genetics team should interpret individual results and guide family screening.